deltatrials
Recruiting PHASE1 NCT05292664

Venetoclax Basket Trial for High Risk Hematologic Malignancies

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

Sponsor: AbbVie

Conditions Acute Leukemia of Ambiguous Lineage Acute Leukemia of Ambiguous Lineage in Relapse Acute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma, Refractory Lymphoblastic Lymphoma, in Relapse Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes, de Novo Therapy-Related Myelodysplastic Syndrome Treatment-Related Acute Myeloid Leukemia
Interventions Azacitidine Calaspargase Pegol Cytarabine Dexamethasone Dexrazoxane Doxorubicin Erwinia asparaginase Hydrocortisone Leucovorin Methotrexate Venetoclax Vincristine
Updated 19 times since 2022 Last updated: Mar 10, 2026 Started: Mar 29, 2023 Primary completion: Jul 2, 2028 Completion: Jul 2, 2030

A PHASE1 clinical study on Acute Leukemia of Ambiguous Lineage and Acute Leukemia of Ambiguous Lineage in Relapse, this trial is actively recruiting participants. The trial is conducted by AbbVie and has accumulated 19 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – ~Oct 2025 · 4 months · monthly snapshot~Oct 2025 – ~Mar 2026 · 5 months · monthly snapshot~Mar 2026 – present · 20 days · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  2. Oct 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Jun 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  4. Mar 2025 — Jun 2025 [monthly]

    Recruiting PHASE1

  5. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Oct 2024 — Feb 2025 [monthly]

    Recruiting PHASE1

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jan 2024 — May 2024 [monthly]

    Recruiting PHASE1

  6. Oct 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  7. Apr 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  8. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  9. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  10. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  11. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE1

  13. Jun 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1

  14. Apr 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Andrew E. Place, MD
  • Boston Children's Hospital
  • Children's Cancer Research Fund
  • Gateway for Cancer Research
  • Servier
  • University of Colorado, Denver
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations